Top

Published in:

Open Access 01-06-2020 | Anemia | Review Article

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Authors: Yujin Li, Shirong Zhu, Weiyi Liu, Jing Ming, Xueying Wang, Xiaomei Hu

Published in: Annals of Hematology | Issue 6/2020

Abstract

Ruxolitinib is a targeted drug to treat myelofibrosis (MF). Ruxolitinib has significant advantages in spleen reduction and increasing 5-year overall survival (OS), and ruxolitinib-based combinations might provide more benefits than ruxolitinib monotherapy. In this review, we focus on the data of ruxolitinib-based combinations therapies and treatment-related adverse events (AEs) and safety. We analyzed and summarized the data of ruxolitinib-based combinations. Ruxolitinib combined with prednisone + thalidomide + danazol (TPD), panobinostat, pracinostat, azacytidine, or hydroxyurea has well reduced spleen. Ruxolitinib combined with danazol or TPD had well therapies in improvement of hemoglobin (Hgb) and platelets (PLT). Most ruxolitinib-based combinations therapies showed a superior benefit on reduced treatment-related AEs than ruxolitinib monotherapy. Treatment-related AEs and dose modification affect the safety and tolerability of ruxolitinib-based combinations. Genetic testing before treatment is recommended. To provide better clinical guidance, comparisons of these randomized controlled trials with the trials of ruxolitinib alone are necessary. This review suggests that the clinical application of ruxolitinib-based combinations is worth waiting for.

Spivak JL (2010) Narrative review: thrombocytosis, polycythemia vera, and JAK2 mutations: the phenotypic mimicry of chronic myeloproliferation. Ann Intern Med 152(5):300–306. https://doi.org/10.7326/0003-4819-152-5-201003020-00008 CrossRefPubMed

Rumi E, Cazzola M (2017) Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 129(6):680–692. https://doi.org/10.1182/blood-2016-10-695957 CrossRefPubMedPubMedCentral

Cervantes F (2014) How I treat myelofibrosis. Blood 124(17):2635–2642. https://doi.org/10.1182/blood-2014-07-575373 CrossRefPubMed

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061. https://doi.org/10.1016/S0140-6736(05)71142-9 CrossRefPubMed

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057–1069. https://doi.org/10.1038/s41375-018-0077-1 CrossRefPubMedPubMedCentral

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544 CrossRefPubMed

Michiels JJ (2015) Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. World J Crit Care Med 4(3):230–239. https://doi.org/10.5492/wjccm.v4.i3.230 CrossRefPubMedPubMedCentral

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405. https://doi.org/10.1056/NEJMoa1312542 CrossRefPubMedPubMedCentral

Verstovsek S, Mesa RA, Gotlib J et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55. https://doi.org/10.1186/s13045-017-0417-z CrossRefPubMedPubMedCentral

10.

Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN (2013) Ruxolitinib for myelofibrosis–an update of its clinical effects. Clin Lymphoma Myeloma Leuk 13(6):638–645. https://doi.org/10.1016/j.clml.2013.09.006 CrossRefPubMedPubMedCentral

11.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013) The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol 161(4):508–516. https://doi.org/10.1111/bjh.12274 CrossRefPubMedPubMedCentral

12.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807. https://doi.org/10.1056/NEJMoa1110557 CrossRefPubMedPubMedCentral

13.

Kuykendall AT, Shah S, Talati C, al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS (2018) Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol 97(3):435–441. https://doi.org/10.1007/s00277-017-3194-4 CrossRefPubMed

14.

Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88–99. https://doi.org/10.1016/S1470-2045(16)30558-7 CrossRefPubMed

15.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J (2017) SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 35(34):3844–3850. https://doi.org/10.1200/JCO.2017.73.4418 CrossRefPubMedPubMedCentral

16.

Samuelson BT, Vesely SK, Chai-Adisaksopha C, Scott BL, Crowther M, Garcia D (2016) The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis 27(6):648–652. https://doi.org/10.1097/MBC.0000000000000446 CrossRefPubMed

17.

McMullin MF, Harrison CN, Niederwieser D et al (2015) The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol 4:26. https://doi.org/10.1186/s40164-015-0021-2 CrossRefPubMedPubMedCentral

18.

Palandri F, Palumbo GA, Bonifacio M et al (2017) Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget 8(45):79073–79086. https://doi.org/10.18632/oncotarget.18674 CrossRefPubMedPubMedCentral

19.

Dioverti MV, Abu SO, Tande AJ (2018) Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature. Infect Dis (Lond) 50(5):381–387. https://doi.org/10.1080/23744235.2017.1390248 CrossRef

20.

Abdelrahman RA, Begna KH, Al-Kali A et al (2015) Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol 169(1):77–80. https://doi.org/10.1111/bjh.13262 CrossRefPubMed

21.

Jain T, Mesa R (2016) The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. Expert Rev Anticancer Ther 16(11):1101–1108. https://doi.org/10.1080/14737140.2016.1233061 CrossRefPubMed

22.

Bose P, Verstovsek S (2017) JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood 130(2):115–125. https://doi.org/10.1182/blood-2017-04-742288 CrossRefPubMedPubMedCentral

23.

Fontana V, Dudkiewicz P, Ahn ER, Horstman L, Ahn YS (2011) Danazol therapy combined with intermittent application of chemotherapy induces lasting remission in myeloproliferative disorder (MPD): an alternative for the elderly with advanced MPD. Hematology 16(2):90–94. https://doi.org/10.1179/102453311X12902908412075 CrossRefPubMed

24.

Shimoda K, Shide K, Kamezaki K, Okamura T, Harada N, Kinukawa N, Ohyashiki K, Niho Y, Mizoguchi H, Omine M, Ozawa K, Haradaa M (2007) The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. Int J Hematol 85(4):338–343. https://doi.org/10.1532/IJH97.06135 CrossRefPubMed

25.

Cervantes F, Isola IM, Alvarez-Larran A et al (2015) Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 94(11):1791–1796. https://doi.org/10.1007/s00277-015-2435-7 CrossRefPubMed

26.

Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C, Camoriano J, Tibes R, Gano K, Palmer J, Mesa R (2017) Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res 60:31–35. https://doi.org/10.1016/j.leukres.2017.06.005 CrossRefPubMed

27.

Xu ZF, Qin TJ, Zhang HL et al (2019) Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study. Zhonghua Xue Ye Xue Za Zhi 40(1):24–28. https://doi.org/10.3760/cma.j.issn.0253-2727.2019.01.005 CrossRefPubMed

28.

Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S (2015) Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058–1063. https://doi.org/10.3324/haematol.2015.126821 CrossRefPubMedPubMedCentral

29.

Mascarenhas J, Marcellino BK, Lu M, Kremyanskaya M, Fabris F, Sandy L, Mehrotra M, Houldsworth J, Najfeld V, el Jamal S, Petersen B, Moshier E, Hoffman R (2020) A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leuk Res 88:106272. https://doi.org/10.1016/j.leukres.2019.106272 CrossRefPubMed

30.

Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S (2019) A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767–1774. https://doi.org/10.1080/10428194.2018.1543876 CrossRefPubMedPubMedCentral

31.

Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood 126(3):291–299. https://doi.org/10.1182/blood-2015-01-621664 CrossRefPubMedPubMedCentral

32.

Daver N, Cortes JE, Pemmaraju N, Jabbour EJ, Bose P, Zhou L, Pierce S, van Derbur S, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S (2016) Ruxolitinib (RUX) in combination with 5-azacytidine (AZA) as therapy for patients (pts) with myelofibrosis (MF). Blood 128(22):1127. https://doi.org/10.1182/blood.V128.22.1127.1127 CrossRef

33.

Breccia M, Luciano L, Pugliese N, Rossi E, Tiribelli M, Scalzulli E, Bonifacio M, Martino B, Latagliata R, Benevolo G, Caocci G, Binotto G, Martinelli V, Cavo M, Pane F, de Stefano V, Foà R, Palandri F (2019) Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. Ann Hematol 98(8):1933–1936. https://doi.org/10.1007/s00277-019-03727-6 CrossRefPubMed

34.

Crisà E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D (2018) The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Br J Haematol 182(5):701–704. https://doi.org/10.1111/bjh.15450 CrossRefPubMed

35.

Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuk F, Kröger N (2014) JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 28(8):1736–1738. https://doi.org/10.1038/leu.2014.86 CrossRefPubMed

36.

Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V (2016) Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant 22(3):432–440. https://doi.org/10.1016/j.bbmt.2015.10.005 CrossRefPubMed

37.

Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, al-Ali HK (2014) Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant 49(2):179–184. https://doi.org/10.1038/bmt.2013.173 CrossRefPubMed

38.

Lussana F, Rambaldi A (2017) Inflammation and myeloproliferative neoplasms. J Autoimmun 85:58–63. https://doi.org/10.1016/j.jaut.2017.06.010 CrossRefPubMed

39.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL (2015) JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 5(3):316–331. https://doi.org/10.1158/2159-8290.CD-14-0736 CrossRefPubMedPubMedCentral

40.

Kastritis E, Dimopoulos MA (2007) The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 8(4):497–509. https://doi.org/10.1517/14656566.8.4.497 CrossRefPubMed

41.

Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS (2017) Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer 70:22–33. https://doi.org/10.1016/j.ejca.2016.10.018 CrossRefPubMed

42.

Tabarroki A, Tiu RV (2012) Immunomodulatory agents in myelofibrosis. Expert Opin Investig Drugs 21(8):1141–1154. https://doi.org/10.1517/13543784.2012.693913 CrossRefPubMed

43.

Tefferi A (2018) Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 93(12):1551–1560. https://doi.org/10.1002/ajh.25230 CrossRefPubMed

44.

Cervantes F, Vannucchi AM, Kiladjian JJ, al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047–4053. https://doi.org/10.1182/blood-2013-02-485888 CrossRefPubMed

45.

Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM (2006) Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106(9):1974–1984. https://doi.org/10.1002/cncr.21827 CrossRefPubMed

46.

Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B (2004) Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 22(3):424–431. https://doi.org/10.1200/JCO.2004.08.160 CrossRefPubMed

47.

Duan M, Zhou D (2019) Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone. Hematology 24(1):516–520. https://doi.org/10.1080/16078454.2019.1631509 CrossRefPubMed

48.

Luo X, Xu Z, Li B, Qin T, Zhang P, Zhang H, Fang L, Pan L, Hu N, Qu S, Zhang Y, Huang G, Peter Gale R, Xiao Z (2018) Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer J 8(1):9. https://doi.org/10.1038/s41408-017-0029-4 CrossRefPubMedPubMedCentral

49.

Bělohlávková P, Maisnar V, Voglová J et al (2016) Improvement of anaemia in patients with primary myelofibrosis by low-dose thalidomide and prednisone. Acta Medica (Hradec Kralove) 59(2):50–53. https://doi.org/10.14712/18059694.2016.89 CrossRef

50.

Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101(7):2534–2541. https://doi.org/10.1182/blood-2002-09-2928 CrossRefPubMed

51.

Shreenivas A, Mascarenhas J (2018) Emerging drugs for the treatment of myelofibrosis. Expert Opin Emerg Drugs 23(1):37–49. https://doi.org/10.1080/14728214.2018.1445718 CrossRefPubMed

52.

Mascarenhas J, Sandy L, Lu M, Yoon J, Petersen B, Zhang D, Ye F, Newsom C, Najfeld V, Hochman T, Goldberg JD, Hoffman R (2017) A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leuk Res 53:13–19. https://doi.org/10.1016/j.leukres.2016.11.015 CrossRefPubMed

53.

Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, Goldberg JD, Hoffman R (2013) A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 161(1):68–75. https://doi.org/10.1111/bjh.12220 CrossRefPubMed

54.

Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A, Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P, Levine RL, Bhalla KN (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114(24):5024–5033. https://doi.org/10.1182/blood-2009-05-222133 CrossRefPubMedPubMedCentral

55.

Evrot E, Ebel N, Romanet V, Roelli C, Andraos R, Qian Z, Dolemeyer A, Dammassa E, Sterker D, Cozens R, Hofmann F, Murakami M, Baffert F, Radimerski T (2013) JAK1/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clin Cancer Res 19(22):6230–6241. https://doi.org/10.1158/1078-0432.CCR-13-0905 CrossRefPubMed

56.

Ribrag V, Harrison CN, Heidel FH et al (2013) A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (PMF), post–polycythemia vera MF (PPV-MF), or post–essential thrombocythemia MF (PET-MF): identification of the recommended phase 2 dose. Blood 122(21):4045. https://doi.org/10.1182/blood.V122.21.4045.4045 CrossRef

57.

Kiladjian JJ, Heidel FH, Vannucchi AM, Ribrag V, Passamonti F, Hayat A, Conneally E, Martino B, Kindler T, Lipka DB, Acharyya S, Gopalakrishna P, Ide SE, Loechner S, Mu S, Harrison CN (2014) Efficacy, safety, and confirmation of the recommended phase 2 dose of ruxolitinib plus panobinostat in patients with intermediate or high-risk myelofibrosis. Blood 124(21):711. https://doi.org/10.1182/blood.V124.21.711.711 CrossRef

58.

Harrison CN, Kiladjian JJ, Heidel FH, Vannucchi AM, Passamonti F, Hayat A, Conneally E, Martino B, Kindler T, Lipka DB, Acharyya S, Gopalakrishna P, Ide S, Liu T, Mu S, Ribrag V (2015) Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (pts) with myelofibrosis (MF). Blood 126(23):4060. https://doi.org/10.1182/blood.V126.23.4060.4060 CrossRef

59.

Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S (2013) A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer 60(11):1868–1874. https://doi.org/10.1002/pbc.24694 CrossRefPubMed

60.

Chu QC, Nielsen TO, Alcindor T et al (2015) A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200dagger. Ann Oncol 26(5):973–981. https://doi.org/10.1093/annonc/mdv033 CrossRefPubMed

61.

Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group. J Clin Oncol 20(10):2429–2440. https://doi.org/10.1200/JCO.2002.04.117 CrossRefPubMed

62.

Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562–569. https://doi.org/10.1200/JCO.2009.23.8329 CrossRefPubMed

63.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132(16):1664–1674. https://doi.org/10.1182/blood-2018-04-846626 CrossRefPubMedPubMedCentral

64.

McGann PT, Flanagan JM, Howard TA et al (2012) Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer 59(2):254–257. https://doi.org/10.1002/pbc.23365 CrossRefPubMed

65.

Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T (2007) A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21(2):277–280. https://doi.org/10.1038/sj.leu.2404473 CrossRefPubMed

66.

Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 152(1):81–88. https://doi.org/10.1111/j.1365-2141.2010.08430.x CrossRefPubMed

67.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, For the COMFORT-I investigators (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100(4):479–488. https://doi.org/10.3324/haematol.2014.115840 CrossRefPubMedPubMedCentral

68.

Tefferi A (2011) How I treat myelofibrosis. Blood 117(13):3494–3504. https://doi.org/10.1182/blood-2010-11-315614 CrossRefPubMed

69.

Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR, American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116(20):4045–4059. https://doi.org/10.1182/blood-2010-08-300541 CrossRefPubMed

70.

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin M, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, European LeukemiaNet (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761–770. https://doi.org/10.1200/JCO.2010.31.8436 CrossRefPubMedPubMedCentral

71.

Thiele J, Kvasnicka HM, Dietrich H et al (2005) Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 20(3):879–889. https://doi.org/10.14670/HH-20.879 CrossRefPubMed

72.

Alchalby H, Yunus DR, Zabelina T et al (2012) Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 157(1):75–85. https://doi.org/10.1111/j.1365-2141.2011.09009.x CrossRefPubMed

73.

Kröger N, Holler E, Kobbe G et al (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114(26):5264–5270. https://doi.org/10.1182/blood-2009-07-234880 CrossRefPubMed

74.

Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Thiede C, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander AR, Kröger N (2010) Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 116(18):3572–3581. https://doi.org/10.1182/blood-2009-12-260588 CrossRefPubMed

75.

Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC, Akard LP, Hoffman R, Rondelli D (2008) Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 141(1):80–83. https://doi.org/10.1111/j.1365-2141.2008.07010.x CrossRefPubMed

76.

Lavi N, Rowe JM, Zuckerman T (2017) Allogeneic stem-cell transplantation for myelofibrosis. Curr Opin Hematol 24(6):475–480. https://doi.org/10.1097/MOH.0000000000000381 CrossRefPubMed

77.

Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO, Cahn JY, de Coninck E, Dhedin N, Bernard M, Rio B, Buzyn A, Huynh A, Bilger K, Bordigoni P, Contentin N, Porcher R, Socié G, Milpied N (2011) Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 152(3):331–339. https://doi.org/10.1111/j.1365-2141.2010.08417.x CrossRefPubMed

78.

Verstovsek S, Hasserjian RP, Pozdnyakova O et al (2018) PRM-151 in myelofibrosis: efficacy and safety in an open label extension study. Blood 132(Supplement 1):686. https://doi.org/10.1182/blood-2018-99-115362 CrossRef

79.

Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK, Hoffman R, Silver RT, Kremyanskaya M, Pozdnyakova O, Hasserjian RP, Trehu E, Salama ME, Kantarjian HM, Gotlib J (2015) PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks. Blood 126(23):56. https://doi.org/10.1182/blood.V126.23.56.56 CrossRef

80.

Bose P, Verstovsek S (2018) Management of myelofibrosis-related cytopenias. Curr Hematol Malig Rep 13(3):164–172. https://doi.org/10.1007/s11899-018-0447-9 CrossRefPubMed

81.

Bose P, Alfayez M, Verstovsek S et al (2019) New concepts of treatment for patients with myelofibrosis. Curr Treat Options in Oncol 20(1):5. https://doi.org/10.1007/s11864-019-0604-y CrossRef

82.

Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20(7):1900–1909. https://doi.org/10.1158/1078-0432.CCR-13-1710 CrossRefPubMed

83.

Ruiz-Borrego M, Jimenez B, Antolín S, García-Saenz JA, Corral J, Jerez Y, Trigo J, Urruticoechea A, Colom H, Gonzalo N, Muñoz C, Benito S, Caballero R, Bezares S, Carrasco E, Rojo F, Martín M (2019) A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. Investig New Drugs 37(1):98–108. https://doi.org/10.1007/s10637-018-0614-9 CrossRef

84.

Gupta V, Koschmieder S, Harrison CN, Cervantes F, Heidel FH, Drummond M, Rey J, Hurh E, Bao W, Rampersad A, Kalambakas S, Vannucchi AM (2014) Phase 1b dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. Blood 124(21):712. https://doi.org/10.1182/blood.V124.21.712.712 CrossRef

85.

Moyo TK, Sochacki A, Ayers GD, Byrne MT, Strickland SA, Mohan SR, Harrison J, Berry LD, Dudley CV, Severs R, Dugger L, Miskin HP, Cavers A, Sportelli P, Michaelis LC, Mesa RA, Savona MR (2016) Preliminary results from a phase I dose escalation trial of ruxolitinib and the PI3Kδ inhibitor TGR-1202 in myelofibrosis. Blood 128(22):1125–1125. https://doi.org/10.1182/blood.V128.22.1125.1125 CrossRef

86.

Moyo TK, Palmer J, Huang Y et al (2018) Resurrecting response to ruxolitinib: a phase I study of ruxolitinib and umbralisib (TGR-1202) in ruxolitinib-experienced myelofibrosis. Haematologica S133

87.

Bixby D, Noppeney R, Lin TL, Cortes J, Krauter J, Yee K, Medeiros BC, Krämer A, Assouline S, Fiedler W, Dimier N, Simmons BP, Riehl T, Colburn D (2019) Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. Br J Haematol 185(3):595–598. https://doi.org/10.1111/bjh.15571 CrossRefPubMed

88.

Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F (2018) A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. J Hematol Oncol 11(1):122. https://doi.org/10.1186/s13045-018-0661-x CrossRefPubMedPubMedCentral

89.

Mascarenhas J, Hoffman R (2013) A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121(24):4832–4837. https://doi.org/10.1182/blood-2013-02-482232 CrossRefPubMed

90.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5(2):e73–e81. https://doi.org/10.1016/S2352-3026(17)30237-5 CrossRefPubMed

91.

Passamonti F, Maffioli M (2018) The role of JAK2 inhibitors in MPNs 7 years after approval. Blood 131(22):2426–2435. https://doi.org/10.1182/blood-2018-01-791491 CrossRefPubMed

92.

Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O’Neill P, Clark J, Hunter D, Assad A, Hoffman R, Verstovsek S (2017) Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica 102(2):327–335. https://doi.org/10.3324/haematol.2016.151126 CrossRefPubMedPubMedCentral

93.

Economides MP, Verstovsek S, Pemmaraju N et al (2019) Novel therapies in myeloproliferative neoplasms (MPN): beyond JAK inhibitors. Curr Hematol Malig Rep 14(5):460–468. https://doi.org/10.1007/s11899-019-00538-4 CrossRefPubMed

94.

Tefferi A, Barosi G, Mesa RA et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood 108(5):1497–1503. https://doi.org/10.1182/blood-2006-03-009746 CrossRefPubMed

95.

Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395–1398. https://doi.org/10.1182/blood-2013-03-488098 CrossRefPubMedPubMedCentral

96.

Martínez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Díaz-Beyá M, Cervantes F (2010) Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 89(12):1233–1237. https://doi.org/10.1007/s00277-010-1019-9 CrossRefPubMed

97.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PAW, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098–4103. https://doi.org/10.1200/JCO.2012.42.3863 CrossRefPubMedPubMedCentral

98.

Renfro LA, Sargent DJ (2017) Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 28(1):34–43. https://doi.org/10.1093/annonc/mdw413 CrossRefPubMed

99.

Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ (2020) An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin 70:125–137. https://doi.org/10.3322/caac.21600 CrossRefPubMedPubMedCentral

100.

Griesshammer M, Sadjadian P (2017) The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. Expert Opin Pharmacother 18(18):1929–1938. https://doi.org/10.1080/14656566.2017.1404574 CrossRefPubMed

Title: Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Authors: Yujin Li
Shirong Zhu
Weiyi Liu
Jing Ming
Xueying Wang
Xiaomei Hu
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Anemia
Ruxolitinib
Published in: Annals of Hematology / Issue 6/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04028-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials

Impact of blood pressure early after allogeneic hematopoietic cell transplantation on clinical outcomes

Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma

Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas

Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials